| Subject: | FDA Notifies Consumers and Healthcare Professionals about Three Medications Menactra, Strattera, Paxil - Paroxetine HCL and Paxil CR Controlled-Release Tablets |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Tue, 11 Oct 2005 - 11:43 am |
| Menactra (Meningococcal Conjugate Vaccine A, C, Y, and W135)
Audience: Neurological and other Healthcare Professionals, and Consumers
On October 3, 2005, the FDA and CDC notified consumers and healthcare providers of five reports of Guillain Barre Syndrome (GBS) following administration of Meningococcal Conjugate Vaccine A, C, Y, and W135 (trade name Menactra), manufactured by Sanofi Pasteur. It is not known yet whether the vaccine caused these cases or if the cases are coincidental, however,... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
Related MCN Products:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
